Hanmi Holdings Co. Ltd. has patented proteolysis targeting chimeras (PROTACs) comprising a cereblon (CRBN)-binding moiety coupled to a histone acetyltransferase p300 (EP300)-targeting moiety through a linker acting as EP300 degradation inducers reported to be useful for the treatment of cancer.
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to selectively recognize and eliminate tumor cells that express DEM-TXX.
Boundless Bio Inc. has obtained IND approval from the FDA for its novel kinesin oral degrader program, BBI-940. A first-in-human trial (KOMODO-1) for metastatic breast cancer is expected to begin in the first half of this year.
A new method, based on gene editing with oligonucleotides and functional analyses, identifies which variants of DNA repair genes associated with Lynch syndrome are truly harmful and which are not. Scientists at The Netherlands Cancer Institute have developed this technique and classified these gene variants in both coding and noncoding regions, distinguishing those that are pathogenic from those that are benign.
Interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors have been reported in several Daewoong Pharmaceutical Co. Ltd. patents. They are described as potentially useful for the treatment of cancer and autoimmune diseases.
The University of Washington has divulged antibody-drug conjugates (ADCs) comprising an antibody targeting HER2 (erbB2) linked to monomethyl auristatin E (MMAE) through a linker. They are described as useful for the treatment of cancer.
The University of Michigan has disclosed pyrrolo[1,2-a]-azocine analogues acting as as inhibitor of apoptosis proteins (IAP) inhibitors. As such, they are reported to be potentially useful for the treatment of AIDS, cancer, infections, psoriasis, multiple sclerosis, vascular disorders, inflammatory disorders and autoimmune diseases.
Copper is an essential trace element with critical roles in several biological processes; therefore, its levels are tightly regulated by multiple mechanisms. Researchers from Sun Yat-Sen University (Guangzhou, China) and collaborators recently described the design of a series of novel copper ionophores with varying n-alkyl chain lengths.
Unlike patients with HER2+ tumors, there is an unmet clinical need for patients with HER2-low expression cancers, which are refractory to trastuzumab. Sanofi SA has developed TPP-45142, a T-cell engager consisting of two nanobody domains targeting HER2 and T-cell receptor (TCR) fused to an Fc region harboring the F234A and L235A mutations to inhibit effector function.
RSS
